BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer. This Review of treatment options after BCG failure focuses on principles of optimal management emerging therapies, thus enabling a synthesis of recommendations for management for such patients.

Nature reviews. Urology. 2017 Feb 21 [Epub]

Ashish M Kamat, Marc Colombel, Debasish Sundi, Donald Lamm, Andreas Boehle, Maurizio Brausi, Roger Buckley, Raj Persad, Joan Palou, Mark Soloway, J Alfred Witjes

Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, Texas 77054, USA., Department of Urology, Claude Bernard University, Hôpital Edouard Herriot, Urologie - Pavillon V, 5 Place d'Arsonval, 69003 Lyon, France., Department of Surgery, University of Arizona and BCG Oncology, 3815 East Bell Road, Suite 1210, Phoenix, Arizona 85032, USA., Department of Urology, HELIOS Agnes Karll Hospital, Am Hochkamp 21, 23611 Bad Schwartau, Germany., Department of Urology, AUSL Modena, B. Ramazzini Hospital, Via G. Molinari, 1, 41012 Carpi-Modena, Italy., Department of Urology, North York General Hospital, 1333 Sheppard Avenue East, Suite 222, North York, Ontario M2J 1V1, Canada., Department of Urology/Surgery, Southmead Hospital &Bristol Urological Institute, Brunel Building, Southmead Road, Bristol BS10 5NB, UK., Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Carrer de Cartagena, 340-350, 08025 Barcelona, Spain., Division of Urologic Oncology, Memorial Cancer Institute, Memorial Health System, 20801 Biscayne Boulevard, Suite 203, Aventura, Florida 33180, USA., Department of Urology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HGB, Nijmegen, Netherlands.